Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
Nvidia, Levi Strauss & Co & Hims & Hers Health Inc
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
GET MORE AI-GENERATED SIGNALS: September 30, 2024, 17:16 pm ET, BY Rick O.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Hims & Hers is a fantastic value despite its high on-the-surface P/E ratio and valuation metrics. Click here to read why HIMS ...
Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...
Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback